UT Health cures diabetic mice without side effects

Researchers at the University of Texas Health Science Center have attempted to eliminate insulin shots for those with type 2 diabetes, focusing on working with mice.

The approach increased the types of pancreatic cells responsible for secreting insulin in mice. While receiving a U.S. patent in January, the method uses the approach of gene transfer, which uses a virus as a carrier to introduce genes to the pancreas to activate the production of digestive enzymes to make insulin.

"A major problem we have in the field of Type 1 diabetes is hypoglycemia (low blood sugar)," said Bruno Doiron, PhD, assistant professor of medicine at UT Health. "The gene transfer we propose is remarkable because the altered cells match the characteristics of beta cells. Insulin is only released in response to glucose. We don't need to replicate all of the insulin-making function of beta cells. Only 20 percent restoration of this capacity is sufficient for a cure of Type 1."

In testing on mice, the researchers tried to regulate blood sugar, showing an improvement of current insulin therapy and medications. In fact, the approach cured diabetes in mice.

“It worked perfectly," said Doiron. "We cured mice for one year without any side effects. That's never been seen. But it's a mouse model, so caution is needed. We want to bring this to large animals that are closer to humans in physiology of the endocrine system."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”